TERBINAFINE
It is a synthetic antifungal compound and is an allylamine derivative. It acts by inhibition of squalene epoxidase in the fungal cell membrane.Fungal infections of the skin caused by dermatophytes like Trichophyton spp., Microsporum spp., Epidermophyton spp. Orally indicated in the treatment of onychomycosis caused by dermatophytes.
Adults: 250 mg for a duration of 2-6 weeks in Tinea pedia, 2-4 weeks in Tinea corporis/cruris, 2-4 weeks in Candidiasis, 4 weeks in Tinea capitis, 6-12 weeks in onychomycosis. Children: 2 yrs. and old: upto 20 kg bodyweight and above): 62.5 mg once a day; 20 to 40 kg body weight: 125 mg once a day; > 40 kg bodyweight: 250 mg once a day.
Hypersensitivity to terbinafine.
Pre-existing liver or renal impairment, irregular use or premature discontinuation carries the risk of recurrence of infection. Elderly patients, pregnancy, lactation.
Gastrointestinal symptoms, skin reactions, taste disturbance, hepatobiliary dysfunction, haematological disorders.
Negligible potential for inhibiting or inducing the clearance of drugs that are metabolised via cytochrome system e.g. cyclosporin, tolbutamide or oral contraceptives. Drugs that induce or inhibit microsomal enzymes may interfere with terbinafine metabolism. Terbinafine decreases caffeine clearance.
